One of the leading complaints in the emergency department is chest pain and the timely detection of a heart attack is essential. The Johns Hopkins Hospital presented an abstract at the American College of Cardiology (ACC) conference in March that utilized VentraCor's VectraplexECG System. The abstract, entitled "New Cardiac Electrical Biomarker Measured on 12-Lead ECG Strongly Correlates With High Sensitivity Troponin in Patients Admitted to the Emergency Department to Rule Out Acute Myocardial Ischemic Injury," was presented by Larisa Tereshchenko, M.D., Ph.D., FAHA, of The Johns Hopkins Hospital.

Continuing its commitment to provide best-in-class medical devices for the prevention of recurrent pulmonary embolism (PE), Argon Medical Devices Inc. launched the OptionELITE Retrievable Vena Cava Filter. The OptionELITE IVC Filter, designed by Rex Medical LP, provides the clinician with the same safe and trusted design now enhanced for ease of delivery and retrievability.

Toshiba America Medical Systems Inc. has introduced the Aplio 500 and Aplio 300 CV ultrasound systems to help clinicians more accurately and efficiently diagnose cardiovascular disease. Compact and easy-to-use, Aplio 500 CV and Aplio 300 CV deliver exceptional image quality and advanced technologies to improve patient diagnoses and treatment.

Siemens Healthcare has introduced a new version of its cardiovascular imaging and information system. From routine to advanced readings, the new version of syngo Dynamics helps streamline workflows and optimize clinical utilization.

Corgenix Medical Corp. has announced that Atherotech Diagnostics Lab will carry its AspirinWorks Test for determining aspirin effect.

SunTech Medical has updated its line of automated blood pressure (BP) monitoring with the Tango M2 cardiac stress BP monitor. The new product provides accurate BP measurements during exercise and cardiac stress testing where noise and motion often make manual measurements difficult.

Endosense has announced that the results of its EFFICAS I prospective multi-center study have led to the development of guidelines for target and minimum contact force (CF), as well as minimum Force Time Integral (FTI), during the catheter ablation treatment of paroxysmal atrial fibrillation (PAF).

iRhythm Technologies Inc. announced clinical study findings showing that use of the Zio Patch resulted in a change in treatment strategy for nearly one-third of patients with paroxysmal atrial fibrillation (AF). The data, which was published in Pacing and Clinical Electrophysiology (PACE) Journal on March 12, showed that the Zio Patch ambulatory cardiac monitoring system demonstrated improved clinical accuracy and detection of potentially malignant arrhythmias in AF patients compared with a 24-hour Holter monitor in the same patients.

CHAMPION PHOENIX clinical study anti-platelet therapy cangrelor ACC 13

The experimental anti-clotting drug cangrelor solidly outperformed commonly used clopidogrel in a large global trial of patients who underwent coronary stent procedures, according to data from the phase III CHAMPION PHOENIX study presented at the American College of Cardiology’s 62nd Annual Scientific Session.

 

BioControl Medical has received U.S. Food and Drug Administration (FDA) approval to begin the third and largest phase of INOVATE-HF (INcrease Of VAgal TonE in Heart Failure), a global, multi-center, investigational device exemption (IDE) clinical study of the company’s CardioFit system for heart failure. The approval, which is based on the FDA’s safety review of the first two successful completed phases, allows unconditional study expansion to full enrollment of 650 patients at 80 centers worldwide.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now